# Robert A. Fenstermaker

Source: https://onco.cc/people/robert-fenstermaker/  
OnCo record `robert-fenstermaker` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Robert Fenstermaker invented SurVaxM, a survivin-targeted vaccine in late-stage trials for glioblastoma.

## Summary

Robert A. Fenstermaker is Chair of the Department of Neurosurgery and Director of the Neuro-Oncology Program at Roswell Park Comprehensive Cancer Center. He is a neurosurgeon-scientist known for inventing SurVaxM, a survivin peptide mimic vaccine for glioblastoma that showed encouraging phase 2 results and advanced to a randomised trial in newly diagnosed disease. His selected paper reports the phase 2 trial of SurVaxM with temozolomide in newly diagnosed glioblastoma. He continues to work on cancer vaccines and glioma while leading neurosurgery at Roswell Park.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Chair, Department of Neurosurgery; Director, Neuro-Oncology Program
- Specialisms: Glioblastoma; Cancer vaccines; Survivin

## Sources

- Roswell Park profile: https://www.roswellpark.org/robert-fenstermaker
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Fenstermaker%20RA%5BAuthor%5D

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- technologies: [Off-the-shelf cancer vaccines](https://onco.cc/technologies/shared-antigen-vaccine/)
- institutions: [Roswell Park Comprehensive Cancer Center](https://onco.cc/institutions/roswell-park/)

---
JSON: https://onco.cc/api/v1/entities/robert-fenstermaker.json